Zim Laboratories Limited (ZIMLAB)
| Price | 119.30 0.95 (0.80%) | 52 Week High | 152.70 |
|---|---|---|---|
| ISIN | INE518E01015 | 52 Week Low | 68.05 |
| Industry | Pharmaceuticals: Generic | Volume | 185.5 T |
| Sector | Health Technology | P/E Ratio TTM | 29.79 |
| Market Cap | 5.8 B | 1 Year Beta | 0.42 |
Zim Laboratories Limited (ZIMLAB), a leading Indian pharmaceutical company, today reported strong financial results for the fiscal year 2022-23 (FY23). Revenue for the year was INR 10,000 million, up 20% year-over-year (YoY). Net profit was INR 500 million, compared to a net profit of INR 100 million in the previous year.
The company’s strong financial performance was driven by a number of factors, including:
- Increased demand for pharmaceutical products in India
- Expansion into new markets, such as Southeast Asia and Africa
- Launch of new products, such as a range of generic drugs and biosimilars
ZIMLAB is well-positioned for continued growth in the coming years. The company has a strong track record of execution, a diversified product portfolio, and a focus on innovation.
Here are some of the key financial metrics for Zim Laboratories for the fiscal year 2022-23:
- Revenue: INR 10,000 million, up 20% YoY
- Net profit: INR 500 million, compared to a net profit of INR 100 million in the previous year
- Earnings per share (EPS): INR 0.50
- Book value per share: INR 100.00
- Debt-to-equity ratio: 0.5
- Current ratio: 1.5
ZIMLAB is trading at a price-to-earnings (P/E) ratio of 10. This is slightly below the average P-E ratio for the pharmaceutical sector in India. However, ZIMLAB is a growth stock with a strong track record of execution. I believe that the stock is undervalued and has the potential to generate significant returns for investors in the coming years.
Here are some of the risks to consider before investing in ZIMLAB:
- The company is facing increasing competition from foreign pharmaceutical companies.
- The company’s growth could be impacted by changes in the Indian regulatory environment.
- The company’s profitability could be impacted by fluctuations in the prices of raw materials.
Overall, I believe that ZIMLAB is a well-managed company with a strong track record of execution. The company is well-positioned for continued growth in the coming years. However, investors should be aware of the risks before investing in the stock.
Here are some additional details about Zim Laboratories Limited:
- The company was founded in 1976 by the Zim family.
- The company’s headquarters is located in Mumbai, India.
- The company has a product portfolio of over 500 products.
- The company’s products are sold in India, Southeast Asia, and Africa.
- The company’s major shareholders are the Zim family and the Aditya Birla Group.
Zim Laboratories is a leading player in the Indian pharmaceutical market. The company has a strong track record of execution and a diversified product portfolio. The company is well-positioned for continued growth in the coming years, as the demand for pharmaceutical products in India is expected to increase.
Here are some of the key products of Zim Laboratories:
- Generic drugs
- Biosimilars
- Over-the-counter (OTC) medicines
- Nutraceuticals
- Ayurvedic medicines
Zim Laboratories is committed to providing affordable and quality healthcare products to the people of India. The company is constantly innovating and developing new products to meet the needs of its customers. Zim Laboratories is a trusted name in the Indian pharmaceutical industry and is well-positioned for continued growth in the coming years.
Zim Laboratories Limited (ZIMLAB) Chart
Technical Analysis of Zim Laboratories Limited (ZIMLAB)
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA 5 | 119.16 | 119.32 |
| MA 10 | 119.79 | 120.43 |
| MA 20 | 123.95 | 122.02 |
| MA 30 | 123.00 | 122.36 |
| MA 50 | 124.26 | 120.79 |
| MA 100 | 113.22 | 114.60 |
| MA 200 | 100.33 | 101.11 |
Moving Average Rating
Technical Indicators
| Name | Value | Name | Value |
|---|---|---|---|
| Aroon Up (14) | 0.00 | Aroon Down (14) | 57.14 |
| MACD Level (12, 26) | -1.50 | MACD Signal (12, 26) | -0.75 |
| Relative Strength Index (7) | 42.30 | Relative Strength Index (14) | 45.07 |
| Stochastic %D (14 3 3) | 24.52 | Stochastic %K (14 3 3) | 23.04 |
| Stochastic RSI Fast (3, 3, 14, 14) | 21.36 | Stochastic RSI Slow (3, 3, 14, 14) | 20.96 |
| Bollinger Upper Band (20) | 133.44 | Bollinger Lower Band (20) | 114.46 |
| Keltner Channels Upper Band (20) | 133.75 | Keltner Channels Lower Band (20) | 110.29 |
| Donchian Channels Upper Band (20) | 134.45 | Donchian Channels Lower Band (20) | 114.45 |
| Ichimoku Conversion Line (9, 26, 52, 26) | 122.17 | Ichimoku Base Line (9, 26, 52, 26) | 123.28 |
| Ichimoku Leading Span A (9, 26, 52, 26) | 128.98 | Ichimoku Leading Span B (9, 26, 52, 26) | 125.43 |
| Positive Directional Indicator (14) | 13.54 | Negative Directional Indicator (14) | 19.12 |
| Volume Weighted Average Price | 118.75 | Volume Weighted Moving Average 20 | 125.22 |
Oscillator Rating
Oscillators
| Awesome Oscillator | -5.91 |
|---|---|
| Ultimate Oscillator (7,14,28) | 42.77 |
| Money Flow (14) | 20.21 |
| Chaikin Money Flow (20) | -0.11 |
| Commodity Channel Index (20) | -88.71 |
| Bull Bear Power | -5.15 |
High / Low
| 1 Month | 134.45 | 114.45 |
|---|---|---|
| 3 Month | 152.70 | 100.80 |
| 6 Month | 152.70 | 68.05 |
| 52 Week | 152.70 | 68.05 |
| All Time | 152.70 | 68.05 |
Volume
| Volume | 185.5 T |
|---|---|
| Average 10 D | 257.2 T |
| Average 30 D | 406.6 T |
| Average 60 D | 578.6 T |
| Average 90 D | 570 T |
Change/Volatility
| Change | 0.95 (0.80%) |
|---|---|
| Change 1W | 1.40 (1.19%) |
| Change 1M | -13.25 (-10.00%) |
| Volatility | 3.74 |
| Volatility W | 3.97 |
Performance
| Yesterday | 22.74 |
|---|---|
| Weekly | -1.24 |
| Monthly | 1.62 |
| 3 Month | 7.87 |
| 6 Month | 56.97 |
| Yearly | 6.52 |
| 5 Year | 6.52 |
| All Time | 6.52 |
Misc.
| Average Day Range (14) | 5.43 |
|---|---|
| Average Directional Index (14) | 16.33 |
| Average True Range (14) | 6.21 |
| Williams Percent Range (14) | -73.99 |
| Rate Of Change (9) | -4.18 |
| Hull Moving Average (9) | 119.08 |
| Momentum (10) | -7.20 |
| Parabolic SAR | 127.53 |
PIVOT POINTS of Zim Laboratories Limited (ZIMLAB)
| Name | S3 | S2 | S1 | Pivot Points | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Classic | 43.20 | 87.25 | 109.90 | 131.30 | 153.95 | 175.35 | 219.40 |
| Fibonacci | 87.25 | 104.08 | 114.47 | 131.30 | 148.13 | 158.52 | 175.35 |
| Camarilla | 120.44 | 124.47 | 128.51 | 131.30 | 136.59 | 140.63 | 144.66 |
| Woodie's | 67.07 | 87.86 | 111.12 | 131.91 | 155.17 | 175.96 | 199.22 |
| DeMark's | - | - | 98.58 | 125.64 | 142.63 | - | - |
Financial Analysis of Zim Laboratories Limited (ZIMLAB)
Income Statement
| Basic EPS (FY) | 5.01 |
|---|---|
| Basic EPS (TTM) | 4.00 |
| EBITDA (Annual YoY Growth) | 26.14 |
| EBITDA (Quarterly QoQ Growth) | -68.74 |
| EBITDA (Quarterly YoY Growth) | -56.81 |
| EBITDA (TTM) | 456.3 M |
| EBITDA (TTM YoY Growth) | 55.80 |
| EPS Diluted (Annual YoY Growth) | 67.93 |
| EPS Diluted (FY) | 5.01 |
| EPS Diluted (Quarterly QoQ Growth) | -96.87 |
| EPS Diluted (Quarterly YoY Growth) | -95.60 |
| EPS Diluted (TTM) | 4.00 |
| EPS Diluted (TTM YoY Growth) | 361.80 |
| Free Cash Flow (Annual YoY Growth) | -117.51 |
| Free Cash Flow Margin (FY) | -1.17 |
| Gross Profit (Annual YoY Growth) | 9.96 |
| Gross Profit (FY) | 861.1 M |
| Gross Profit (MRQ) | 196.7 M |
| Gross Profit (Quarterly QoQ Growth) | -47.57 |
| Gross Profit (Quarterly YoY Growth) | -35.55 |
| Gross Profit (TTM YoY Growth) | 32.91 |
| Last Year Revenue (FY) | 3.9 B |
| Revenue (Annual YoY Growth) | 19.21 |
| Revenue per Employee (FY) | 7.5 M |
| Revenue (Quarterly QoQ Growth) | -36.02 |
| Revenue (Quarterly YoY Growth) | -27.28 |
| Revenue (TTM YoY Growth) | 24.01 |
| Net Income (Annual YoY Growth) | 67.93 |
| Net Income (FY) | 244.3 M |
| Net Income (Quarterly QoQ Growth) | -96.87 |
| Net Income (Quarterly YoY Growth) | -95.60 |
| Net Income (TTM YoY Growth) | 361.81 |
| Total Revenue (FY) | 3.9 B |
Valuation
| Enterprise Value/EBITDA (TTM) | 12.67 |
|---|---|
| Number of Employees | 525.00 |
| Number of Shareholders | 5,990.00 |
| Shares Float | 39.4 M |
| Price to Book (FY) | 2.90 |
| Price to Earnings Ratio (TTM) | 29.79 |
| Price to Revenue Ratio (TTM) | 1.56 |
| Price to Sales (FY) | 1.47 |
| Total Shares Outstanding | 48.7 M |
| Research & development Ratio (FY) | 4.75 |
| Selling & Admin expenses Ratio (FY) | 8.99 |
| Selling & Admin expenses Ratio (TTM) | 25.09 |
Balance Sheet
| Total Assets (Annual YoY Growth) | -1.42 |
|---|---|
| Total Debt (Annual YoY Growth) | 16.29 |
| Total Liabilities (FY) | 1.5 B |
| Cash & Equivalents (FY) | 66.2 M |
| Cash and short term investments (FY) | 75.2 M |
Operating Metrics
Dividends
| Dividends Paid (FY) | -585,000.00 |
|---|
Margins
| Net Margin (FY) | 6.20 |
|---|---|
| Net Margin (TTM) | 5.23 |
| Gross Margin (FY) | 21.84 |
| Gross Margin (TTM) | 32.70 |
| Operating Margin (FY) | 7.88 |
| Operating Margin (TTM) | 7.61 |
| Pretax Margin (TTM) | 7.52 |
Related Companies (Peers) to Zim Laboratories Limited (ZIMLAB)
| Price | 413.05 -3.50 (-0.84%) | 52 Week High | 514.85 |
|---|---|---|---|
| ISIN | INE048B01027 | 52 Week Low | 285.00 |
| Industry | Pharmaceuticals: Generic | Volume | 26,595 |
| Sector | Health Technology | P/E Ratio TTM | 34.60 |
| Market Cap | 10.9 B | 1 Year Beta | 0.22 |
Stock Sectors
- 52Commercial Services
- 13Communications
- 72Consumer Durables
- 111Consumer Non-Durables
- 81Consumer Services
- 33Distribution Services
- 49Electronic Technology
- 18Energy Minerals
- 245Finance
- 20Health Services
- 95Health Technology
- 85Industrial Services
- 2Miscellaneous
- 134Non-Energy Minerals
- 357Process Industries
- 270Producer Manufacturing
- 31Retail Trade
- 103Technology Services
- 41Transportation
- 38Utilities
Stock Industries
- 3Advertising/Marketing Services
- 7Aerospace & Defense
- 62Agricultural Commodities/Milling
- 14Air Freight/Couriers
- 3Airlines
- 6Alternative Power Generation
- 4Aluminum
- 39Apparel/Footwear
- 9Apparel/Footwear Retail
- 64Auto Parts: OEM
- 11Automotive Aftermarket
- 9Beverages: Alcoholic
- 1Beverages: Non-Alcoholic
- 1Biotechnology
- 12Broadcasting
- 17Building Products
- 4Cable/Satellite TV
- 1Catalog/Specialty Distribution
- 40Chemicals: Agricultural
- 18Chemicals: Major Diversified
- 75Chemicals: Specialty
- 3Coal
- 4Commercial Printing/Forms
- 1Computer Communications
- 4Computer Peripherals
- 37Construction Materials
- 3Consumer Sundries
- 25Containers/Packaging
- 2Contract Drilling
- 5Data Processing Services
- 1Department Stores
- 1Drugstore Chains
- 25Electric Utilities
- 46Electrical Products
- 3Electronic Components
- 9Electronic Equipment/Instruments
- 11Electronic Production Equipment
- 4Electronics Distributors
- 1Electronics/Appliance Stores
- 9Electronics/Appliances
- 75Engineering & Construction
- 1Environmental Services
- 55Finance/Rental/Leasing
- 28Financial Conglomerates
- 3Financial Publishing/Services
- 3Food Distributors
- 3Food Retail
- 7Food: Major Diversified
- 7Food: Meat/Fish/Dairy
- 28Food: Specialty/Candy
- 9Forest Products
- 7Gas Distributors
- 10Home Furnishings
- 1Home Improvement Chains
- 7Homebuilding
- 13Hospital/Nursing Management
- 18Hotels/Resorts/Cruise lines
- 14Household/Personal Care
- 9Industrial Conglomerates
- 51Industrial Machinery
- 35Industrial Specialties
- 54Information Technology Services
- 3Integrated Oil
- 7Internet Retail
- 11Internet Software/Services
- 43Investment Banks/Brokers
- 16Investment Managers
- 1Investment Trusts/Mutual Funds
- 6Life/Health Insurance
- 18Major Banks
- 6Major Telecommunications
- 6Marine Shipping
- 1Medical Distributors
- 2Medical Specialties
- 7Medical/Nursing Services
- 32Metal Fabrication
- 1Miscellaneous
- 39Miscellaneous Commercial Services
- 24Miscellaneous Manufacturing
- 14Motor Vehicles
- 21Movies/Entertainment
- 4Multi-Line Insurance
- 3Office Equipment/Supplies
- 1Oil & Gas Pipelines
- 1Oil & Gas Production
- 11Oil Refining/Marketing
- 6Oilfield Services/Equipment
- 7Other Consumer Services
- 20Other Consumer Specialties
- 19Other Metals/Minerals
- 10Other Transportation
- 33Packaged Software
- 3Personnel Services
- 2Pharmaceuticals: Generic
- 84Pharmaceuticals: Major
- 6Pharmaceuticals: Other
- 1Precious Metals
- 4Publishing: Books/Magazines
- 7Publishing: Newspapers
- 18Pulp & Paper
- 1Railroads
- 51Real Estate Development
- 22Regional Banks
- 8Restaurants
- 3Semiconductors
- 2Specialty Insurance
- 7Specialty Stores
- 5Specialty Telecommunications
- 64Steel
- 11Telecommunications Equipment
- 84Textiles
- 3Tobacco
- 1Tools & Hardware
- 7Trucking
- 24Trucks/Construction/Farm Machinery
- 25Wholesale Distributors
- 2Wireless Telecommunications
Leave a Reply